VistaGen Therapeutics, Inc. (VTGN)
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
$81.71M
Mr. Shawn K. Singh J.D.
34.00
South San Francisco, CA
Oct 18, 2010
-3.25
$-0.93
2.38
2.86
-25.78%
-0.52
3.52
0.44
2.54
-308.94%
-268.41%
Similar stocks (16)
Kezar Life Sciences, Inc.
KZR
Tempest Therapeutics, Inc.
TPST
Cocrystal Pharma, Inc.
COCP
Synlogic, Inc.
SYBX
iBio, Inc.
IBIO
Xenetic Biosciences, Inc.
XBIO
Galera Therapeutics, Inc.
GRTX
Revelation Biosciences, Inc.
REVB
Dermata Therapeutics, Inc.
DRMA
Bio-Path Holdings, Inc.
BPTH
Quoin Pharmaceuticals, Ltd.
QNRX
Panbela Therapeutics, Inc.
PBLA
Histogen Inc.
HSTO
TRACON Pharmaceuticals, Inc.
TCON
eFFECTOR Therapeutics, Inc.
EFTR
Better Therapeutics, Inc.
BTTX
ETF Exposure (8)
iShares Micro-Cap ETF
IWC
0.02429%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (16)
Kezar Life Sciences, Inc.
KZR
Tempest Therapeutics, Inc.
TPST
Cocrystal Pharma, Inc.
COCP
Synlogic, Inc.
SYBX
iBio, Inc.
IBIO
Xenetic Biosciences, Inc.
XBIO
Galera Therapeutics, Inc.
GRTX
Revelation Biosciences, Inc.
REVB
Dermata Therapeutics, Inc.
DRMA
Bio-Path Holdings, Inc.
BPTH
Quoin Pharmaceuticals, Ltd.
QNRX
Panbela Therapeutics, Inc.
PBLA
Histogen Inc.
HSTO
TRACON Pharmaceuticals, Inc.
TCON
eFFECTOR Therapeutics, Inc.
EFTR
Better Therapeutics, Inc.
BTTX
ETF Exposure (8)
iShares Micro-Cap ETF
IWC
0.02429%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%